Bimekizumab (Bimzelx®) is now being considered for coverage under the British Columbia Ministry of Health’s PharmaCare program. By filling out a questionnaire on a website called Your Voice, you can provide feedback about Bimzelx® for the treatment of active ankylosing spondylitis and active psoriatic arthritis in adults.
You can give input if you are a B.C. resident and have ankylosing spondylitis or psoriatic arthritis, a caregiver to someone with ankylosing spondylitis or psoriatic arthritis, or if your group represents people who live with ankylosing spondylitis or psoriatic arthritis.
Click here to submit your patient input. Your feedback will be anonymized and collated with others who choose to provide it to ACE for submission on their behalf. Please provide your input to us by Thursday, March 21 so that we may submit the questionnaire in time for the deadline.
The submission deadline is March 26, 2024. Patients and caregivers may give their input directly to BC PharmaCare through the links below.
Please click on the information sheet links below to learn more about Bimzelx® and the questionnaire links below to let BC PharmaCare hear Your Voice. There are separate links for each disease:
For ankylosing spondylitis
- To view the information sheet for Bimzelx® for the treatment of ankylosing spondylitis: click here
- To complete the Questionnaire as a patient, caregiver, or patient group representative: click here
For psoriatic arthritis
To complete the Questionnaire as a patient, caregiver, or patient group representative: click here
To view the information sheet for Bimzelx® for the treatment of psoriatic arthritis: click here
Carrie
person with rheumatoid arthritis